前收市價 | 124.68 |
開市 | 125.95 |
買盤 | 123.98 x 200 |
賣出價 | 124.16 x 200 |
今日波幅 | 122.22 - 126.21 |
52 週波幅 | 89.00 - 213.91 |
成交量 | |
平均成交量 | 1,621,593 |
市值 | 19.746B |
Beta 值 (5 年,每月) | 1.19 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -7.34 |
業績公佈日 | 2024年5月02日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 152.15 |
The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers. The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this year compared with 2023, and still sees its adjusted operating margin to be about 20%. U.S. life sciences Illumina's first-quarter revenue was $1.08 billion, above analysts' estimate of $1.05 billion.
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.